SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-PSMA-617 Radionuclide Therapy

被引：12

作者：

Hope, Thomas A. ^{[1
]}

Antonarakis, Emmanuel S. ^{[2
]}

Bodei, Lisa ^{[3
]}

Calais, Jeremie ^{[4
]}

Iravani, Amir ^{[5
]}

Jacene, Heather ^{[6
,7
]}

Koo, Phillip J. ^{[8
]}

Morgans, Alicia K. ^{[9
]}

Osborne, Joseph R. ^{[10
]}

Tagawa, Scott T. ^{[11
]}

Taplin, Mary-Ellen ^{[9
]}

Sartor, Oliver ^{[12
]}

Morris, Michael J. ^{[13
]}

机构：

[1] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA

[2] Univ Minnesota, Mason Canc Ctr, Minneapolis, MN USA

[3] Mem Sloan Kettering Canc Ctr, Dept Radiol, Mol Imaging & Therapy Serv, New York, NY USA

[4] UCLA, David Geffen Sch Med, Dept Mol & Med Pharmacol, Ahmanson Translat Theranost Div, Los Angeles, CA USA

[5] Univ Washington, Dept Radiol, Seattle, WA 98195 USA

[6] Brigham & Womens Hosp, Dept Radiol, Boston, MA USA

[7] Dana Farber Canc Inst, Dept Imaging, Boston, MA 02115 USA

[8] Banner MD Anderson Canc Ctr, Phoenix, AZ USA

[9] Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA

[10] Weill Cornell Med, Mol Imaging & Therapeut, Dept Radiol, New York, NY USA

[11] Weill Cornell Med Coll, Dept Med, New York, NY USA

[12] Mayo Clin, Rochester, MN USA

[13] Mem Sloan Kettering Canc Ctr, Genitourinary Oncol Serv, New York, NY USA

来源：

JOURNAL OF NUCLEAR MEDICINE | 2023年 / 64卷 / 09期

关键词：

RESISTANT PROSTATE-CANCER; SURVIVAL; CABAZITAXEL; SAFETY;

D O I：

10.2967/jnumed.123.265952

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

Prostate-specific membrane antigen (PSMA) is a transmem-brane carboxypeptidase that is highly expressed in prostate cancer. Radioligand therapy (RLT) with 177Lu-labeled compounds has shown clinical benefit, and the U.S. Food and Drug Administration (FDA) approved 177Lu-PSMA-617 (177Lu-vipivotide tetraxetan [Pluvicto; Novartis]) for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC) after progressing on taxane-based chemotherapy and at least 1 line of androgen recep-tor pathway inhibitors (ARPIs). This document aims to provide standardized guidance through expert consensus for the selection and management of patients being treated with 177Lu-PSMA RLT.

引用

页码：1417 / 1423

页数：7

共 50 条

[1] NANETS/SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy
Hope, Thomas A.
Bodei, Lisa
Chan, Jennifer A.
El-Haddad, Ghassan
Fidelman, Nicholas
Kunz, Pamela L.
Mailman, Josh
Menda, Yusuf
Metz, David C.
Mittra, Erik S.
Pryma, Daniel A.
Reidy-Lagunes, Diane L.
Singh, Simron
Strosberg, Jonathan R.
JOURNAL OF NUCLEAR MEDICINE, 2020, 61 (02) : 222 - 227
[2] A Hangover Under 177Lu-PSMA-617 Therapy
Poterszman, Nathan
Somme, Laura
Bund, Caroline
Hutt, Emilie
Somme, Francois
CLINICAL NUCLEAR MEDICINE, 2024, 49 (06) : 582 - 583
[3] Radiation Dosimetry in 177Lu-PSMA-617 Therapy
Jackson, Price
Hofman, Michael
McIntosh, Lachlan
Buteau, James Patrick
Kumar, Aravind Ravi
SEMINARS IN NUCLEAR MEDICINE, 2022, 52 (02) : 243 - 254
[4] 177Lu-Vipivotide Tetraxetan (177Lu-PSMA-617, Pluvicto) Therapy
Clements, Sarah
Tempesta, Daniel
Jacene, Heather
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY, 2022, 50 (03) : 213 - 214
[5] 177Lu-PSMA-617: Brazilian Experience
Villas Boas, Cristian Wieczorek
Silva, Jefferson de Jesus
Benedetto, Raquel
Mengatti, Jair
De Araujo, Elaine Bortoleti
JOURNAL OF NUCLEAR MEDICINE, 2019, 60
[6] Experimental 177Lu-PSMA-617 radioligand therapy in a patient with extended metastasized leiomyosarcoma
Jueptner, Michael
Marx, Marlies
Zuhayra, Maaz
Luetzen, Ulf
NUKLEARMEDIZIN-NUCLEAR MEDICINE, 2019, 58 (04): : 328 - 330
[7] 177Lu-PSMA-617 Therapy in a Patient on Haemodialysis with End Stage Renal Failure
MacFarlane, L.
Eifer, M.
Saghebi, J.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S248 - S248
[8] Radiation exposure after 177Lu-DOTATATE and 177Lu-PSMA-617 therapy
Mair, Christian
Warwitz, Boris
Fink, Katharina
Scarpa, Lorenza
Nilica, Bernhard
Maffey-Steffan, Johanna
Buxbaum, Sabine
Virgolini, Irene J.
ANNALS OF NUCLEAR MEDICINE, 2018, 32 (07) : 499 - 502
[9] Radiation exposure after 177Lu-DOTATATE and 177Lu-PSMA-617 therapy
Christian Mair
Boris Warwitz
Katharina Fink
Lorenza Scarpa
Bernhard Nilica
Johanna Maffey-Steffan
Sabine Buxbaum
Irene J. Virgolini
Annals of Nuclear Medicine, 2018, 32 : 499 - 502
[10] Single-Time-Point Dosimetry of 177Lu-PSMA-617 Radionuclide Therapy with SPECT/CT
Burkerr, Brian J.
RADIOLOGY-IMAGING CANCER, 2023, 5 (02):

← 1 2 3 4 5 →